HopeStage
Back to all studies
CompletedNCT01637922

Drug Interactions With Hepatitis C Treatment in People Taking Methadone or Buprenorphine

About this titleRead the official source — NCT01637922
Medication studyAges 18–64United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 64 years.

Listed locations
Atlanta and 2 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateAugust 2012
Recruitment status
Completed
Enrollment listed in the registry
34
Sponsor
Boehringer Ingelheim
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 64 Years
Official registry ID
NCT01637922
Official title
Show the full official title

Effect of Multiple Dosing With BI 201335 on the Safety, Pharmacokinetics and Pharmacodynamics of Steady-state Methadone and Buprenorphine/Naloxone in Subjects on Stable Addiction Management Therapy

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Atlanta · Overland Park · Salt Lake City

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Boehringer Ingelheim.

Did this study involve medication?

Yes. The study involved medication, including BI 201335.

Who was this study for?

Listed age limits: 18 years to 64 years.

Want to explore more studies?

Explore studies